Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,667 questions · 21,760 findings · 2,177 reviews

No studies found 4,173 · 19.2%GRADE not reported 2,300 · 10.6%Very low 5,276 · 24.2%Low 5,764 · 26.5%Moderate 3,298 · 15.2%High 949 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings table ‐ Providing information about the residents? fall risk vs usual care

Residents with at least one psychotropic medication ‐ not measured · older people in all long‐term care settings

The review found no eligible studies for this question.

1 finding from 1 review

Organisational interventions vs usual care

Residents with at least one belt · older people in all long‐term care settings

Summary of findings table ‐ Organisational intervention probably leads to lower residents with at least one belt compared with usual care (moderate certainty).

1 finding from 1 review

Organisational interventions vs usual care

Number of people sustaining one or more fall‐related fractures · older people in all long‐term care settings

Summary of findings table ‐ Organisational intervention showed no clear difference in residents with at least one fall‐related fracture compared with usual care (low certainty).

1 finding from 1 review

Organisational interventions vs usual care

Residents with at least one psychotropic medication · older people in all long‐term care settings

Summary of findings table ‐ Organisational intervention showed no clear difference in residents with at least one psychotropic medication compared with usual care (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).

1 finding from 1 review

Recombinant zoster vaccine vs placebo

Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review